Importantly, clinical analysis revealed higher levels of miR-301a expression in glioma samples with high HIF-1α levels and the percentage of serum exosomal miR-301a (low versus high) was distributed according to the HIF-1α immunohistochemistry score. Here, HIF1A is linked to central nervous system cancer.